The International Serious Adverse Events Consortium is generating novel insights into the genetics and biology of drug-induced serious adverse events, and thereby improving pharmaceutical product development and decision-making.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Impact of New Genomic Technologies on Understanding Adverse Drug Reactions
Clinical Pharmacokinetics Open Access 14 September 2015
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Holden, A. L. The SNP consortium: summary of a private consortium effort to develop an applied map of the human genome. Biotechniques 32, S22–S24 (2002).
Contreras, J. L., Floratos, A. & Holden, A.L. The International Serious Adverse Events Consortium's data sharing model. Nature Biotech. 31, 17–19 (2012).
Contreras, J. L. Bermuda's legacy: policy, patents, and the design of the genome commons. Minn. J. Law Sci. Technol. 12, 61–125 (2011).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Supplementary information
Supplementary information S1 (table)
Summary of case enrolment by iSAEC and status of phase 2 pipeline (PDF 761 kb)
Supplementary information S2 (Box)
Publications from the International Serious Adverse Events Consortium to date (as of September 2014) (PDF 110 kb)
Related links
Rights and permissions
About this article
Cite this article
Holden, A., Contreras, J., John, S. et al. The International Serious Adverse Events Consortium. Nat Rev Drug Discov 13, 795–796 (2014). https://doi.org/10.1038/nrd4441
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrd4441
This article is cited by
-
Predictive validity in drug discovery: what it is, why it matters and how to improve it
Nature Reviews Drug Discovery (2022)
-
Impact of New Genomic Technologies on Understanding Adverse Drug Reactions
Clinical Pharmacokinetics (2016)